What is Leerink Partnrs' Forecast for RVMD Q3 Earnings?

Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) - Leerink Partnrs issued their Q3 2025 earnings per share (EPS) estimates for Revolution Medicines in a research note issued on Wednesday, February 26th. Leerink Partnrs analyst J. Chang forecasts that the company will post earnings of ($1.18) per share for the quarter. The consensus estimate for Revolution Medicines' current full-year earnings is ($3.49) per share. Leerink Partnrs also issued estimates for Revolution Medicines' Q4 2025 earnings at ($1.19) EPS.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($1.12) EPS for the quarter, missing the consensus estimate of ($1.01) by ($0.11).

Other equities research analysts have also issued research reports about the company. Piper Sandler raised their target price on Revolution Medicines from $57.00 to $70.00 and gave the stock an "overweight" rating in a research report on Thursday, November 7th. UBS Group increased their price target on shares of Revolution Medicines from $65.00 to $71.00 and gave the company a "buy" rating in a research note on Wednesday, January 8th. Wedbush restated an "outperform" rating and set a $67.00 price objective on shares of Revolution Medicines in a research report on Thursday. Guggenheim boosted their target price on Revolution Medicines from $82.00 to $87.00 and gave the company a "buy" rating in a report on Tuesday, December 3rd. Finally, HC Wainwright raised their target price on shares of Revolution Medicines from $72.00 to $73.00 and gave the stock a "buy" rating in a research report on Monday. Twelve equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $66.31.

Revolution Medicines Price Performance

Shares of Revolution Medicines stock traded down $2.40 during trading on Monday, hitting $38.34. 1,576,369 shares of the stock were exchanged, compared to its average volume of 1,333,457. The stock has a market cap of $6.45 billion, a price-to-earnings ratio of -10.68 and a beta of 1.45. The firm's 50-day moving average price is $42.15 and its 200 day moving average price is $46.22. Revolution Medicines has a 12-month low of $29.00 and a 12-month high of $62.40.

Insider Activity at Revolution Medicines

In other news, insider Mark A. Goldsmith sold 11,714 shares of the firm's stock in a transaction on Monday, December 16th. The shares were sold at an average price of $45.40, for a total value of $531,815.60. Following the completion of the sale, the insider now owns 325,056 shares in the company, valued at approximately $14,757,542.40. This trade represents a 3.48 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Thilo Schroeder purchased 1,304,347 shares of the company's stock in a transaction dated Thursday, December 5th. The shares were purchased at an average price of $46.00 per share, for a total transaction of $59,999,962.00. Following the completion of the purchase, the director now owns 2,096,612 shares of the company's stock, valued at approximately $96,444,152. This trade represents a 164.64 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold a total of 18,678 shares of company stock worth $847,981 in the last three months. Insiders own 8.00% of the company's stock.

Institutional Trading of Revolution Medicines

A number of institutional investors have recently modified their holdings of RVMD. Vanguard Group Inc. raised its position in Revolution Medicines by 14.7% in the fourth quarter. Vanguard Group Inc. now owns 17,096,455 shares of the company's stock worth $747,799,000 after acquiring an additional 2,185,082 shares in the last quarter. Farallon Capital Management LLC increased its holdings in shares of Revolution Medicines by 17.1% in the 4th quarter. Farallon Capital Management LLC now owns 13,248,692 shares of the company's stock valued at $579,498,000 after purchasing an additional 1,931,000 shares in the last quarter. Janus Henderson Group PLC lifted its stake in shares of Revolution Medicines by 54.5% in the fourth quarter. Janus Henderson Group PLC now owns 9,483,999 shares of the company's stock valued at $414,777,000 after purchasing an additional 3,346,755 shares during the period. Baker BROS. Advisors LP lifted its stake in shares of Revolution Medicines by 4.9% in the fourth quarter. Baker BROS. Advisors LP now owns 7,936,972 shares of the company's stock valued at $347,163,000 after purchasing an additional 367,882 shares during the period. Finally, Nextech Invest Ltd. boosted its holdings in Revolution Medicines by 20.7% during the fourth quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company's stock worth $332,472,000 after buying an additional 1,304,347 shares in the last quarter. 94.34% of the stock is currently owned by hedge funds and other institutional investors.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.